Results and Important Highlights from Q2 2015 - Report on Vital Therapies

Sep 17, 2015, 09:00 ET from

NEW YORK, September 17, 2015 /PRNewswire/ --

ACI Association has initiated research coverage on Vital Therapies, Inc. (NASDAQ: VTL). Select highlights from the internally released reports are being made available to the general public (included below), with access to the entirety of the research available to new members.

Today, membership is open to readers on a complementary basis at the following URL:  

Highlights from our VTL Report include:

  • Performance Highlights from Q2 2015 - On July 30, 2015, the biotherapeutic company Vital Therapies, Inc. announced results for the second quarter ended June 30, 2015. The Company reported a net loss attributable to the common stockholders of $15.1 million or $0.63 per share for Q2 2015, as against the net loss attributable to the common stockholders of $16.3 million or $0.91 per share for the same period a year earlier. During the quarter, total operating expenses grew to $15.1 million from $11.6 million in the year ago period.
  • Key developments from the quarter - As of July 29, 2015, Vital Therapies enrolled eighteenth subject in its second phase 3 clinical trial, VTI-210. This trial is a randomized, controlled, open-label study evaluating the ELAD System in severe acute alcoholic hepatitis subjects who have failed standard therapy.

For VTI-212, a single-arm, phase 2 clinical trial, evaluating the ELAD System in 40 subjects with either fulminant hepatic failure or surgery-induced liver failure, Vital Therapies has enrolled the seventh subject as of July 29, 2015. The top-line results from VTI-212 are expected to be released in 2016.

In July 2015, Vital Therapies presented a poster titled "Expression of Acute-Phase Proteins by ELAD C3A Cells" at the International Liver Transplantation Society's 21st Annual International Congress. The poster described that ELAD's VTL C3A cells produce several key anti-inflammatory proteins that can decrease inflammation of the liver in patients with alcohol-induced liver decompensation (AILD).

The Company also informed that it is on schedule to release top-line results from its VTI-208 clinical trial during the third quarter of 2015.

  • Management's Note - "As we approach data lock and analysis of VTI-208 results, we are pleased to report we are on schedule to report topline results later this quarter," Chief Executive Officer and Co-Chairman of Vital Therapies, Terry Winters, said while commenting on the financial performance. He further added, "VTI-208 is the largest liver support system clinical trial ever conducted, was run on three continents and enrolled 203 subjects. Needless to say we are excitedly awaiting these results."

To find out how this influences our rating on Vital Therapies, Inc., read the full report in its entirety here:


About ACI Association: 

Active Charter Investors Association ("ACI Association") produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. ACI Association has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

ACI Association has not been compensated; directly or indirectly; for producing or publishing this document.


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer"). Rohit Tuli, a CFA® charter holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on sound investment judgment and publicly available information which is believed to be reliable. The Reviewer and the Sponsor have not performed any independent investigations or forensic audits to validate the information herein. Unless otherwise noted, any content outside of this document has no association with the Author, the Reviewer, or the Sponsor (collectively referred to as the "Production Team") in any way. The Production Team is compensated on a fixed monthly basis and do not hold any positions of interest in any of the securities mentioned herein.  


ACI Association, the Author, the Reviewer and the Sponsor (collectively referred to as the "Publishers") are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by the Publishers whatsoever for any direct, indirect or consequential loss arising from the use of this document. The Publishers expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, the Publishers do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither ACI Association nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit


ACI Association is not available to residents of Belarus, Cuba, Canada, Iran, North Korea, Sudan, Syria or Somalia. Do not send email to robottrap (at)

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.